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A B S T R A C T
Background
In patients with unstable angina and non-ST-elevation myocardial infarction (UA/NSTEMI) two strategies are possible: a routine
invasive strategy where all patients undergo coronary angiography shortly after admission and, if indicated, coronary revascularization;
or a conservative strategy where medical therapy alone is used initially with selection of patients for angiography based on clinical
symptoms or investigational evidence of persistent myocardial ischemia.
Objectives
To determine the benefits of an invasive compared to a conservative strategy for treating UA/NSTEMI in the stent era.
Search strategy
The Cochrane Central Register of Controlled Trials (Issue 3 2005), MEDLINE and EMBASE were searched from 1996 to September
2005 with no language restrictions.
Selection criteria
Included studies were prospective trials comparing invasive with conservative strategies in UA/NSTEMI.
Data collection and analysis
We identified 5 studies (7818 participants). Using intention-to-treat analysis with random effects models, summary estimates of relative
risk (95% confidence interval [CI]) were determined for primary end-points of all-cause death, fatal and non-fatal myocardial infarction;
all-cause death or non-fatal myocardial infarction; and refractory angina. Further analysis of included studies was undertaken based on
whether glycoprotein IIb/IIIa receptor antagonists were used routinely. Heterogeneity was assessed using chi-square and variance (I2)
methods.
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Main results
In the all-study analysis, mortality during initial hospitalization showed a trend to hazard with an invasive strategy; relative risk 1.59
(95% CI 0.96 to 2.64). Mortality and myocardial infarction assessed at 2-5 years in two trials were significantly decreased by an
invasive strategy with relative risk of 0.75 (95% CI 0.62 to 0.92) and 0.75 (95% CI 0.61 to 0.91) respectively. The composite end-
point of death or non-fatal myocardial infarction was significantly decreased by an invasive strategy at several time points after initial
hospitalization. The incidence of early (<4 months) and intermediate (6-12 months) refractory angina were both significantly decreased
by an invasive strategy; relative risk 0.47 (95% CI 0.32 to 0.68) and 0.67 (95% CI 0.55 to 0.83) respectively, as were early and
intermediate rehospitalization rates with relative risk 0.60 (95% CI 0.41 to 0.88) and 0.67 (95% CI 0.61 to 0.74) respectively. The
invasive strategy was associated with a two-fold increase in the relative risk of peri-procedural myocardial infarction (as variably defined)
and a 1.7-fold increase in the relative risk of bleeding.
Authors’ conclusions
An early invasive strategy is preferable to a conservative strategy in the treatment of UA/NSTEMI.
P L A I N L A N G U A G E S U M M A R Y
Should all patients with unstable angina and non-ST elevation myocardial infarction be subjected to an invasive strategy
comprising coronary angiography and, if indicated, percutaneous coronary intervention, within 48 hours of admission?
Patients with prolonged or recurrent chest pain, may have a condition called unstable angina or suffer a certain type of heart attack
called non-ST elevation myocardial infarction. These conditions can be managed with two treatment strategies. Several studies have
been done to determine which strategy is superior. In one strategy, the routine invasive strategy, all patients have a catheter inserted to
image their coronary arteries to look for atherosclerotic narrowing. If a significant narrowing or complicated plaque is found then it
may be dilated by means of a balloon catheter being inserted and inflated across the narrowing, and patency of the vessel maintained by
insertion of a metallic stent. In some cases, the narrowing will not be amenable to this approach and surgery to bypass the narrowing
is required. In the other strategy, the conservative strategy, patients are initially treated with drugs and only patients who suffer more
chest pain while receiving drugs or who demonstrate evidence of atherosclerotic narrowing as suggested by other non-invasive tests
(such as stress testing or imaging) undergo coronary angiography and revascularization if indicated.
There has been debate as to which strategy is better. The invasive strategy reduces the incidence of further chest pain or rehospitalization.
Also, long term follow-up from two studies suggests that it reduces the risk of dying and the risk of having another heart attack by one
quarter two to five years following the event. Based on review of all available studies, the invasive strategy is preferable.
B A C K G R O U N D
The diagnosis of acute coronary syndromes
The acute coronary syndromes (ACS) encompass three disorders
of related etiology: ST-elevation myocardial infarction (STEMI),
non-ST elevation myocardial infarction (NSTEMI) and unstable
angina (UA). The management of STEMI differs from that for
UA and NSTEMI which may be considered as one clinical entity
(UA/NSTEMI). The pathogenesis of UA/NSTEMI involves five
non-exclusive causative factors: non-occlusive thrombus on pre-
existing plaque, dynamic obstruction, progressive mechanical ob-
struction, inflammation and secondary unstable angina associated
with increased cardiac work load (Braunwald 1998). Of these fac-
tors, thrombus on pre-existing plaque, i.e. acute plaque change, is
themost common. Indeed, themajority of patients with ACS have
acute change in coronary atherosclerotic plaques, with STEMI
usually associatedwith complete occlusion of the involved vessel(s)
(DeWood 1980) andUA/NSTEMI usually associated with subto-
tal occlusion (DeWood 1986; TIMI-IIIA 1993). The distinction
betweenUA andNSTEMI depends on the presence of myocardial
infarction as determined by markers of myocardial damage such
as Troponin I (TnI), Troponin T (TnT) or creatine kinase (CK-
MB).
Compared to STEMI, NSTEMI has a lower 30 day mortality rate
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but more recurrent ischemia and a similar 1 year mortality rate
(Armstrong 1998). UA/NSTEMI is much more common than
STEMI; in the United States, 1.3 million patients were admitted
to hospital with UA/NSTEMI compared to 350,000 with STEMI
(AHA 1999). Whereas emergency percutaneous coronary revas-
cularization is now a commonly used therapy for treating STEMI
(Cucherat 2003; Antman 2004), the role of angiography and pos-
sible subsequent revascularization is less clear in UA/NSTEMI.
In overview, treatment of UA/NSTEMI initially involves medical
therapy followed by one of two management strategies involving
different rates of angiography and revascularization. The medical
therapies for UA/NSTEMI will be briefly reviewed before the fo-
cus of this review shifts to the management strategies of patients
with UA/NSTEMI.
Initial medical management of UA/NSTEMI
In brief, medical treatments, as outlined in the ACC/AHA guide-
lines (Braunwald 2002) fall into two major groups: anti-ischemic
therapies and anti-platelet/anti-coagulation therapies. Anti-is-
chemic therapies include bed rest, nitroglycerin, beta blocker (or
non-dihydropyridine calcium antagonist if beta blockers are con-
traindicated) and anACE inhibitor. Anti-platelet/anti-coagulation
therapies include aspirin, clopidogrel, heparin and glycoprotein
IIb/IIIa receptor antagonists. Randomized trial evidence to sup-
port use of most of these specific therapies has been published.
Of anti-ischemic treatments, beta blockers have proven efficacy in
patients with evolving myocardial infarction (Hjalmarson 1982;
Yusuf 1988) as well as in patients with UA/NSTEMI (Gottlieb
1986; Muller 1984; Theroux 1985). Non-dihydropyridine cal-
cium channel antagonists have proven efficacy in ACS (Boden
1991; Gibson 1986; Pepine 1998; Tijssen 1987) and are par-
ticularly useful in patients with contraindications to beta block-
ers. Both the early and late administration of ACE inhibitors has
been shown to be beneficial in myocardial infarction (EUROPA
2003; HOPE 2000; Rodrigues 2003). Of the anti-platelet/anti-
coagulation treatments, aspirin has a consistent benefit in UA/
NSTEMI as demonstrated in several clinical trials (Cairns 1985;
Lewis 1983; RISC 1990; Theroux 1988). Likewise, clopidogrel
has been shown to be beneficial in addition to aspirin (CURE
2001). Heparin, in its various forms, has also been shown to
be beneficial in UA/NSTEMI (Gurfinkel 1995; Neri Serneri
1990; RISC 1990; Theroux 1993). The glycoprotein IIb/IIIa re-
ceptor antagonists have proven efficacy in medical treatment of
UA/NSTEMI (Boersma 2002; PRISM-PLUS 1998; PURSUIT
1998; Roffi 2002; Topol 1999) with the exception of abciximab
(Simoons 2001). However, this class of drugs appears to have dif-
ferential effects, depending on the patient’s risk level, with high
risk patients obtaining the most benefit. The glycoprotein IIb/IIIa
receptor antagonists warrant special mention with regard to their
use in invasive procedures; this concept is expanded on later.
Management following initial medical treatment: what is the
role of early coronary angiography and revascularization?
Two different treatment strategies may be followed after initial
medical treatment of UA/NSTEMI: an early invasive strategy of
coronary angiography and, if indicated, revascularization in most
or all patients who have no contraindication to such an approach;
or, a conservative (“ischemia guided”) strategy in which patients
undergo coronary angiography and revascularization only if there
is evidence of recurrent ischemia e.g. recurrent infarction, angina
at rest, dynamic ST changes on ECG or definitive inducible is-
chemia on provocative testing. Proponents of the early invasive
strategy argue that the early determination of coronary anatomy
can be used to tailor therapy, avoid lengthy hospital stays and pre-
vent further events. For example, patients with normal coronary
anatomy and minimal disease may be discharged and the need for
readmission for recurrent pain is virtually eliminated. Those with
coronary disease on angiography can be treated expeditiously ac-
cording to their angiography findings which may include revascu-
larization via percutaneous coronary intervention (PCI) compris-
ing coronary angioplasty with or without insertion of coronary
stent, or coronary artery bypass grafting (CABG). Proponents of
the conservative strategy argue that medical therapy can stabilize
patients, stress testing can identify patients at risk of future events
and who would therefore benefit most from invasive intervention,
and the costs and complications of invasive procedures can be
minimized by using them more selectively. The evidence for the
relative benefits and harms of these two approaches is the subject
of this review.
Interpretation of the evidence from trials: changes in contem-
porary clinical practice
In routine clinical practice, the outcomes of invasive coronary pro-
cedures will vary depending on a number of factors: clinical ex-
pertise (Singh 2000); volume of procedures undertaken (Magid
2000); and methods and protocols used, especially in regards to
pharmacological and procedural co-interventions. Of particular
importance in contemporary practice are the use of glycopro-
tein IIb/IIIa receptor antagonists (CAPTURE 1997; EPIC 1994;
EPILOG 1997; EPISTENT 1998; Karvouni 2003), and use of
coronary artery stents (Al Suwaidi 2004), both of which have been
shown to improve outcomes and reduce complications when used
with invasive procedures. A recent publication by the TIMI study
group highlights the importance of adjunctive therapy in the inva-
sive strategy (Sabatine 2004). The TIMI group undertook two tri-
als with identical enrolment criteria investigating treatment strate-
gies in UA/NSTEMI - TIMI-3b (1995) and TACTICS-TIMI 18
(2001). The two trials were nearly a decade apart and, compared
to TIMI-3b, the more recent TACTICS-TIMI 18 study used pre-
procedural (upstream) glycoprotein IIb/IIIa receptor antagonists
and stents as standard treatment. Importantly, this paper showed
that after adjustment for baseline risk, an early invasive strategy
tended to more favorable results in TACTICS-TIMI 18 than in
TIMI-3b. Consequently, in this review, only studies undertaken in
the stent era were considered for inclusion. Stenting as associated
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with fewermajor adverse cardiovascular events and a reduced need
for emergency cardiac surgery (Al Suwaidi 2004). Specifically, the
reduction in target vessel revascularization associated with stenting
is of particular relevance to trials with longer durations of follow
up. If non-stent studies were to be included, the analysis would un-
der-estimate the benefits of an early invasive strategy on endpoints
such as recurrent angina and rehospitalization (e.g. due to chest
pain). After meeting this review’s requirement of routine stent use,
the included studies were also stratified in further analyses by the
adjunctive use of glycoprotein IIb/IIIa receptor antagonists during
PCI.
O B J E C T I V E S
The objectives of this review are two fold:
(1) To determine the benefits and harms of an early invasive strat-
egy compared to a conservative strategy for the management of
UA/NSTEMI in the stent era;
(2) To determine the benefits and harms of an early invasive
strategy with and without glycoprotein IIb/IIIa receptor antago-
nists versus a conservative strategy for the management of UA/
NSTEMI in the stent era.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Studies for inclusion in this review were randomized controlled
clinical trials comparing invasive and conservative strategies in
patients with UA/NSTEMI in which at least one of this review’s
outcomeswasmeasured. Revascularization approaches in included
studies must consist of PCI or CABG as required. Stents must
be used appropriately in patients undergoing revascularization via
PCI. Studies that did not meet this criterion were not deemed
relevant to current practice and were excluded. The effects on
outcomes of use of glycoprotein IIb/IIIa receptor antagonists were
investigated further by undertaking two further separate analyses
of trials that did and did not routinely use glycoprotein IIb/IIIa
receptor antagonists during percutaneous revascularization.
Analysis 1: All studies that deployed stents routinely in revascu-
larization procedures via PCI regardless of glycoprotein IIb/IIIa
receptor antagonist use;
Analysis 2: Stents and glycoprotein IIb/IIIa receptor antagonists
deployed routinely in revascularization procedures via PCI;
Analysis 3: Stents but not glycoprotein IIb/IIIa receptor antago-
nists deployed routinely in revascularization procedures via PCI.
Types of participants
Included studies recruited men and women who were at least 18
years oldwhohad an episode of anginawith an accelerating pattern
or pain at rest. The episode of pain must have occurred within
72 hours of randomization. Further, the patients were required to
have at least one of the following:
(1) new ST depression;
(2) transient (<20 minute) ST elevation;
(3) ischemic T-wave inversion or T-wave inversion in at least 2
contiguous leads;
(4) elevated levels of cardiac markers i.e. troponins or creatine
kinase (CK-MB);
(5) coronary artery disease, as determined by a history of catheter-
ization, revascularization, or ACS.
Included studies excludedpatients if they had any of the following:
(1) persistent ST elevation (i.e. >20 minutes);
(2) secondary angina (e.g. due to anemia or thyrotoxicosis);
(3) serious systemic disease or major co-morbidities that would
preclude an invasive approach;
(4) severe congestive heart failure or cardiogenic shock.
Types of interventions
All patients with UA/NSTEMI were initially treated with some or
all of the medical therapies discussed in the background; these are
summarized in Table 1. Following initial medical therapy, patients
were randomized to either early invasive or conservative treatment.
The two treatment strategies differed with regard to the use of
angiography and subsequent revascularization rates.
The two management strategies compared are:
(1) routine invasive: routine angiography ±revascularization in all
patients; this is carried out in all eligible patients unless they have
contraindications to angiography;
(2) conservative: angiography ±revascularization only in eligible
patients with evidence of cardiac ischemia e.g. recurrent ischemia,
dynamic ECG changes or a positive stress test.
Revascularization modalities include PCI or CABG depending on
angiographic findings. CABG is indicated in lieu of PCI when one
of the following criteria are met:
• three vessel disease and an ejection fraction (EF) <0.50;
• two vessel disease with proximal left anterior descending
involvement and EF <0.50 or ischemia;
• left main coronary artery disease.
Types of outcome measures
Primary measures
(1) Death: all causes
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(2) Myocardial infarction (this end point only included non-fatal
myocardial infarction in the review protocol but now includes fatal
or non-fatal myocardial infarction)
(3) Death (all causes) or non-fatal myocardial infarction
(4) Refractory angina
Secondary measures
(1) Rehospitalization for acute coronary syndromes
(2) Complications of angiography/revascularization i.e. bleeding,
procedure-related mortality or myocardial infarction
Differentiating peri-PCI enzyme leaks from the outcome measure
of non-fatal myocardial infarction warrants further comment. The
ACC/AHA defines peri-PCI myocardial infarction by either an
elevation in cardiac enzymes or by electrocardiographic criteria.
However, not all included studies involved the routine measure-
ment of cardiac enzymes following PCI. Procedural myocardial
infarction was reported as a safety end point where data were avail-
able.
Prespecified Subgroup Analyses:
For the primary end-point of all-cause death or non-fatal myocar-
dial infarction, the following subgroup analyses were undertaken
where data were available:
• gender;
• troponin status;
• ST-depression on admission;
• TIMI risk score [0-2, 3-4, 5-7] (Antman 2000).
Search methods for identification of studies
The databases searched included: The Cochrane Central Register
of Controlled Trials (CENTRAL) onThe Cochrane Library (Issue
3 2005), MEDLINE (1996 to September 2005) and EMBASE
(1996 to September 2005). No language restrictions were applied.
The restriction of 1996 onwards was applied because of low rates
of stent use prior to that year. The strategy for MEDLINE is
described below:
#1 explode ’Myocardial-Infarction’ /
#2 explode ’Angina-Unstable’ /
#3 unstable angina$
#4 coronary syndrome$
#5 myocardial infarct$
#6 myocardial infarction heart infarct$
#7 nstemi
#8 unstable coronary
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 ischaemi$ adj3 guid$
#11 ischemi$ adj3 guid$
#12 early adj3 invasive
#13 invasive adj3 conservative
#14 ischemi$ adj3 strateg$
#15 ischaemi$ adj3 strateg$
#16 conservative adj3 strateg$
#17 conservative adj3 therap$
#18 conservative adj3 treatment$
#19 conservative adj3 management
#20 interventional adj3 strateg$
#21 interventional adj3 therap$
#22 interventional adj3 treatment$
#23 interventional adj3 management
#24 invasive adj3 strateg$
#25 invasive adj3 therap$
#26 invasive adj3 treatment$
#27 invasive adj3 management
#28 triage adj3 angiograph$
#29 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #
18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or
#27 or #28
#30 #9 and #29
A randomized controlled clinical trial filter was used as described
in the Cochrane Handbook.
Further, reference lists of retrieved articles were searched and ex-
perts in the field contacted for additional information.
Data collection and analysis
Study selection
Two reviewers (MRH, JAD) selected articles independently for in-
clusion in the review. A study was considered eligible for inclusion
if it was a prospective trial that compared the routine invasive with
the conservative strategy in patients with UA/NSTEMI. Specific
exclusion criteria are mentioned in the TYPES OF STUDIES sec-
tion above. Disagreement was resolved first by consensus and then
by consultation with content experts (CNA, IAS).
Data extraction
Data were extracted independently by two reviewers (MRH, JAD)
on data extraction sheets. Disagreement was resolved first by con-
sensus and then by consultationwith content experts (CNA, IAS).
Quality assessment
All included studies were assessed independently by two reviewers
for quality. Please refer to the Table of Included Studies for quality
assessment of the included studies. The criteria used were those
recommended by the Cochrane Heart Group:
(1) Treatment assignment: was treatment assignment truly ran-
dom?
(2) Blinding: were the patients and investigators unaware of the
treatment assignment?
(3) Selection bias after treatment assignment: Were all patients
signed up for the trial accounted for at its conclusion? Were the
conclusions reached by intention to treat analysis?
Statistical considerations
Data were analyzed on an intention to treat basis. Where appro-
priate, data from all trials were combined using the Meta analysis
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software in Review Manager. All the outcome measures of this
review were dichotomous. Data were combined using random ef-
fects modeling to determine a summary estimate of the relative
risk and the 95% confidence interval. Heterogeneity was statisti-
cally assessed using the chi-square test (p<0.10) for all end points
and the I2 statistic (Higgins 2003) for selected end points. The I
2 statistic is displayed on the forest plots for all analyses.
As stated under the heading “types of studies”, all included studies
were further analyzed by assignment to one of two analyses de-
pending on the routine use of glycoprotein IIb/IIIa receptor antag-
onists. We compared the invasive versus the conservative strategy
within each analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
The literature search yielded 12 studies that were considered for
this review. One study was excluded because it was based on a reg-
istry and hence contained observational data (MITI 2000). An-
other study was excluded because it was a post hoc analysis of a
trial comparing hirudin to heparin in ACS patients (GUSTO2b).
Three trials were excluded because they were undertaken in the
pre-stent era or did not encourage the routine use of stents in the
invasive strategy (MATE 1998; TIMI-3b; VANQWISH 1998).
As was already stated, such studies under-estimate the value of the
invasive strategy and are not relevant to current practice. Also, two
studies were excluded because of inappropriate patient selection
or trial design (Neumann 2003; TRUCS 2000). More details on
excluded studies can be found in the table of excluded studies . Five
studies were deemed appropriate for inclusion and are described
in the table of included studies. These five studies are analyzed to-
gether in analysis 1. Two of these studies used a glycoprotein IIb/
IIIa antagonist routinely in the invasive arm; TACTICS-TIMI 18
and ICTUS. These two studies were analyzed together in the pre-
specified analysis 2 (see TYPESOFSTUDIES). The three remain-
ing studies satisfied this review’s stent requirement but did not rou-
tinely use glycoprotein IIb/IIIa antagonists in patients random-
ized to the invasive strategy and were analyzed together as analysis
3 (FRISC-II; RITA-3; VINO 2002). This section discusses some
general design features of the included studies and comments on
the specific differences between the studies.
Design:
All studies were randomized controlled trials (RCTs). Due to the
procedural nature of the intervention, it was presumed that the
patients and treating clinicians were not blinded. However, out-
comes were able to be assessed by a blinded committee. The table
of included studies describes trial design features and includes in-
formation on intention to treat analysis and loss to follow-up.
Populations:
The included studies were heterogeneous in their patient selection
criteria. The inclusion criteria were made up of different combi-
nations of the following core criteria: chest pain, ECG changes,
increased level of cardiac markers or documented history of CAD.
The specific criteria for each study are outlined in the table of
included studies. Clearly, since different criteria were used by dif-
ferent studies, different trials randomized patients with different
levels of risk. Elevated troponins ( Antman 1996; Galvani 1997;
Lindahl 1996) or ECG changes (Cannon 1997) forebode worse
prognosis in UA/NSTEMI and hence trials recruiting these pa-
tients can be expected to have higher event rates. The VINO study
randomized patients who had chest pain, ECG changes and ele-
vated cardiac markers whereas in TACTIC-TIMI 18, 27% of the
trial participants had accelerating/prolonged chest pain with a his-
tory of CAD as the sole entry criteria. In contrast, the entry crite-
ria of the RITA-3 study were explicitly aimed at intermediate risk
patients. The most recent trial in the review, ICTUS, included pa-
tients with a positive troponin and either ischemic ECG changes
or a documented history of CAD.
Interventions:
The interventions compared comprise the invasive or conserva-
tive treatment strategies. In the invasive strategy, all patients were
randomized to receive angiography regardless of symptomatic sta-
tus whereas in the conservative strategy angiography was only
performed in patients with clinical or investigational evidence
of ischemia. Evidence clearly shows that patients with recurrent
ischemia who do not have angiography have worse outcomes
(TRUCS 2000). It is important to note that angiography is a com-
ponent of both strategies and that angiography in the conservative
arm does not represent a “cross over” as long as it was preceded by
myocardial ischemia or evidence for CAD.
Time to Interventions:
Time to angiography after symptom onset may influence efficacy.
The times to angiography after randomization in the routine in-
vasive arms were: mean 6.2 hours in VINO, median 22 hours
in TACTICS-TIMI 18, median 23 hours in ICTUS, median 2
days in RITA-3 and mean 4 days in FRISC-II. The FRISC-II in-
vestigators cited observational data to justify delayed angiography
and postulated that a period of “plaque passivation” prior to an-
giography would be beneficial. However, Neumann 2003 subse-
quently compared an “early invasive” (angiography within 6 hours
of randomization) to “delayed invasive” (angiography in 3-5 days)
in UA/NSTEMI patients and found that early angiography pro-
duced superior outcomes to delayed angiography. This finding
needs to be replicated in further prospective trials and possibly
incorporated into future trials in UA/NSTEMI. Given that the
trials in this review are more consistent with a “delayed invasive”
strategy, it is possible that the available data under-estimate the
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potential effectiveness of the invasive strategy.
Criteria for Ischemia:
There were important differences between trials in the criteria for
ischemia thatwouldmandate angiography in the conservative arm.
In particular, the FRISC-II criteria were widely criticized for being
more stringent than those of the other studies, thereby exaggerat-
ing benefit conferred by the invasive strategy. Further, FRISC-II
did not utilize nuclear imaging or pharmacologic stress testing in
the conservative strategy. Indeed, application of the FRISC-II cri-
teria to the VANQWISH study which recruited similar patients
proved that significant CAD was under-detected in the conserva-
tive arm of the FRISC-II study (Goyal 2002).
Outcomes:
Commonly reported outcomes included death, myocardial infarc-
tion and recurrent angina. Death was reported as all-cause death.
The definition of myocardial infarction varied between the in-
cluded studies but included a combination of chest pain, ECG
changes and elevated cardiac enzymes. Peri-PCI enzyme leaks
without other criteria were not reported as an end point by all stud-
ies but were included as a safety outcomewhere datawere available.
The variable definitions of myocardial infarction are summarized
in Table 2 and show that some of the studies required clinical and/
or ECG changes for the myocardial infarction end points whereas
others only required an increased cardiac marker. Importantly, the
ICTUS trial protocol mandated the routine measurement of CK-
MB after PCI and this constituted the end-point of myocardial
infarction. The significance of peri-PCI enzyme leaks is a subject
of considerable debate (Bhatt 2005; Cutlip 2005). The other trials
in this review did not specify the routine measurement of CK-MB
after PCI per protocol. Since ICTUS and TACTICS-TIMI 18
both employed routine glycoprotein IIb/IIIa receptor antagonists
with PCI and are analyzed together in analysis 2, the TACTICS-
TIMI 18 definition of myocardial infarction was applied to the
ICTUS data in analyzing this outcome for consistency across stud-
ies. In conclusion, the clinical trials differed in their definitions
of myocardial infarction and this should be taken into account
when interpreting the findings of this analysis. Fortunately, end
points such as death are indisputable. Follow up was 6 months in
TACTICS-TIMI 18 &VINO, 12 months in ICTUS, 24 months
in FRISC-II and 5 years in RITA-3; characteristics of the included
studies are summarized in the table of included studies and in
Table 1.
Risk of bias in included studies
Themethodological quality of the included studies is summarized
in the table of included studies.
Effects of interventions
The baseline patient characteristics were equivalent between the
two randomized groups of all the included studies. TACTICS-
TIMI 18 and ICTUS were analyzed together in analysis 2 since
they both involved the routine use of both glycoprotein IIb/IIIa
receptor antagonists and stents. Analysis 3 included studies that
used only stenting routinely and includes RITA-3, FRISC-II and
VINO. Since the included studies reported outcomes after dif-
ferent durations of follow up, end points for meta-analysis were
categorized as being index, early, intermediate or late. “Index” end
points indicate follow up during the initial hospitalization. “Early”
end points indicate a follow up less than or equal to 4 months.
“Intermediate” end points indicate a follow up greater than or
equal to 6 months or less than or equal to 12 months. “Late” end
points indicate a follow up greater than or equal to 2 years. In
studies that supplied end points at various time points in a given
category, the latest follow up outcomes were used. For example,
if outcomes were provided at 6 and 12 months follow up, the 12
month data were used in the analysis.
Analysis 1: All Studies undertaken in the stent era regardless
of glycoprotein IIb/IIIa receptor antagonist use. TACTICS-
TIMI 18, ICTUS, RITA-3, FRISC-II & VINO 2002
Death (Index, Early, Intermediate):
Index death showed a trend to hazard with the early invasive strat-
egy having a relative risk of 1.59 (95% confidence interval 0.96
to 2.64). Early and intermediate death were not improved by an
invasive strategy although late death as reported in FRISC-II and
RITA-3 data was significantly decreased; relative risk 0.75 (95%
confidence interval 0.62 to 0.92). Significant heterogeneity (p=
0.09) was detected in the analysis of intermediate death which is
the only analysis that included data from all 5 included studies.
The I2 statistic for the intermediate death analysis was 51% which
indicates that the finding of heterogeneity cannot be assumed to
be due to chance.
Some of the heterogeneity at the intermediate (6-12 month) time
point may be explained by differences between trials in death rates
standardized to years of study duration shown in Table 02. The
rates were 2.5-2.8% per year for RITA-3, FRISC-II and ICTUS
whereas TACTICS-TIMI 18 had a rate of 7% and VINO a rate
of 27%. For the most part, the levels of risk are concordant with
the inclusion criteria of the studies as described in the table of in-
cluded studies with the exception of ICTUS. As already discussed,
mortality increases as troponin concentrations increase in patients
with ACS (Antman 1996). The ICTUS trial exclusively enrolled
patients with a TnT >0.03 ng/ml and hence may be expected to
have a higher mortality rate. Indeed, in TACTICS-TIMI 18, the
6 month mortality rate for patients with a TnT > 0.01 ng/ml was
4% (Morrow 2001). Since the ICTUS trial recruited patients with
TnT >0.03 ng/ml and had a longer duration of 12 months, the
standardized mortality would be expected to be >4%. Indeed, in
FRISC-II, patients with TnT >0.03 ng/ml had a 12 month mor-
tality rate of 4.2% (Diderholm 2002). Hence the ICTUS partic-
ipants appear to have a lower than expected event rate based on
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event rates from other trials. Differences between trials in baseline
medical therapy do not appear to explain why participants in the
ICTUS trial had a lower mortality than other trials, particularly
when comparing high rates of background medical therapy seen
in both ICTUS and TACTICS-TIMI 18. This observation high-
lights the importance of global risk stratification over the selec-
tion of a single high risk characteristic in predicting risk of future
events.
Another important finding of this analysis was that mortality ben-
efits only become apparent after long term (2-5 year) follow up.
The importance of this observation is that over time, deaths ac-
crue and increase the power of a given study to find a significant
mortality difference. This can be seen by the mortality rates at end
of follow up described in Table 1. The studies with the highest
mortality at end of follow up are those that randomized the high-
est risk patients (VINO) and those that had the longest follow up
(RITA-3). Hence, it may be inappropriate to simply consider out-
comes at one time point e.g. at end of follow up as meta-analyses of
this topic have done (Choudhry 2005; Mehta 2005) since it may
be only on long term follow up that mortality curves diverge. Fur-
ther, absolute risk reductions and numbers needed to treat (NNT)
are meaningless from such analyses unless studies are homogenous
for duration of follow up and risk level of participants. Clearly,
long term studies or those enrolling higher risk participants will
have a smaller NNT compared to those of shorter duration or
involving lower risk patients. The finding of long term benefit is
particularly interesting since the mortality benefit of CABG over
medical therapy for stable angina only emerges after 3 years and
following an early hazard for surgery (Yusuf 1994).
Myocardial Infarction (Index, Early, Intermediate, Late ):
Index myocardial infarction was not significantly affected by an
invasive strategy, although significant heterogeneity was found at
this time point (p <0.01). Possible reasons for this include the use
of glycoprotein IIb/IIIa receptor antagonists in TACTICS-TIMI
18 and the definition of myocardial infarction used by the VINO
investigators which excluded any events in the first 72 hours of
randomization (Table 2). Early myocardial infarction was not sig-
nificantly decreased by an early invasive strategy. Intermediate my-
ocardial infarction included data from all the included studies as
assessed at either 6 or 12 months. There was no benefit for the
early invasive strategy although heterogeneity (p=0.02) was found,
drivenby the results of ICTUS.The I2 statistic for the intermediate
myocardial infarction analysis was 66%, indicating that observed
heterogeneity was not due to chance. This is not a surprising find-
ing considering the different definitions of myocardial infarction
in the included studies (Table 2) and specifically, the routine mea-
surement of cardiac biomarkers after intervention in ICTUS and
the inclusion of these peri-PCI leaks in the myocardial infarction
end point. Late myocardial infarction, based on 2 year FRISC-II
data and 5 year RITA-3 data, was significantly decreased by the
invasive strategy; relative risk 0.75 (95% confidence interval 0.61
to 0.91).
Death or Non-Fatal Myocardial Infarction (Index, Early, In-
termediate, Late):
The ICTUS investigators did not report this end point and the
components of the composite have been analyzed individually
and have shown significant heterogeneity. Index death or non-fa-
tal myocardial infarction was not decreased by an early invasive
strategy; significant heterogeneity was found and possible reasons
include those already discussed for components of the composite.
Early death or non-fatal myocardial infarction, based on 30 day
TACTICS-TIMI 18 data and VINO data, was significantly de-
creased by an invasive strategy with a relative risk of 0.64 (95%
confidence interval 0.45 to 0.92). Intermediate death or non-fatal
myocardial infarction was significantly decreased with an early in-
vasive strategy and included data from all included studies except
for ICTUS; relative risk 0.76 (95% confidence interval 0.62 to
0.94). No significant heterogeneity was found. Late death or non-
fatal myocardial infarction was also significantly decreased; how-
ever both components of this composite achieved statistical sig-
nificance independently as already described. Combining data for
subgroup analysis was not possible because TACTICS-TIMI 18
dichotomized patients at TnT of 0.01 ng/ml and TnI of 0.1 ng/ml
whereas FRISC-II presented data based onTnT levels of 0.1 ng/ml
or 0.3 ng/ml. Gender sub-analysis for intermediate death or non-
fatal myocardial infarction showed that the benefit of the invasive
strategy only reached statistical significance in males; relative risk
of 0.68 (95% confidence interval 0.57 to 0.81). Interestingly, the
data for women showed significant heterogeneity between the 3
studies (p=0.05). No such heterogeneity was noted in the male
data. This might be driven by FRISC-II data where women in the
conservative group had significantly better outcomes than men in
the conservative group; relative risk 0.52 (95% confidence inter-
val 0.36 to 0.75). However, the confidence interval in the female
subgroup was wide and overlapped with that of their male coun-
terparts. This is likely due to the small number of females in the
included studies.
Refractory Angina (Early, Intermediate):
An invasive strategy decreased early refractory angina based on
4 month data from RITA-3; relative risk 0.47 (95% confidence
interval 0.32 to 0.68). Intermediate refractory angina was signifi-
cantly decreased by an early invasive strategy with a relative risk of
0.67 (95% confidence interval 0.55 to 0.83) although significant
heterogeneity (p<0.01) was found at this time point driven by
the results of ICTUS. The null effect on this end point found in
ICTUS is surprising given that this study recruited only troponin
positive participants. Indeed, a retrospective analysis of troponin
positive patients fromTACTIC-TIMI 18 showed that 94%of tro-
ponin positive patients had significant angiographic CAD, 79%
of which were revascularized (PCI or CABG) at index hospital-
ization (Dokainish 2005). Hence the trial participants in ICTUS
would be expected to have high rates of angiographic CAD would
be expected to show considerable symptomatic improvement with
an invasive strategy. A possible explanation for this difference in
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outcomes is that 20% of patients enrolled in ICTUS had PCI or
CABG prior to randomization, indicating good baseline control
of symptomatic angina.
Rehospitalization (Early, Intermediate):
The invasive strategy was associated with an early relative risk of
0.60 (95% confidence interval 0.41 to 0.88) and an intermediate
relative risk of 0.67 (95% confidence interval 0.61 to 0.74).
Analysis 2: Routine use of both stents and glycoprotein IIb/
IIIa receptor antagonists. TACTICS-TIMI 18 and ICTUS
This analysis included trials that are as close as possible to an
“ideal” invasive strategy; i.e. a strategy that involved the routine
use of both glycoprotein IIb/IIIa receptor antagonists and stents.
Unfortunately, the ICTUS trial only reported outcomes at 1 year
and did not include the composite end point of death or non-fatal
myocardial infarction. Hence, much of the data regarding early
follow up is based solely on the results of TACTICS-TIMI 18.
Death (Index, Early, Intermediate):
There was no difference between the treatment strategies at any of
the time points assessed. Data fromTACTICS-TIMI 18 suggest a
trend to increased index death and early death (at 30 days) in the
invasive arm but this did not reach statistical significance. Inter-
mediate death was not different between the treatment strategies
when 6 month data fromTACTICS-TIMI 18 and 12 month data
from ICTUS were combined. In TACTIC-TIMI 18, the risk of
death was not reduced by an early invasive strategy even in higher
risk patients with TnI levels >0.1 ng/ml.
Myocardial Infarction (Index, Early, Intermediate)
Based on TACTIC-TIMI 18 data, the invasive strategy was asso-
ciated with a relative risk of 0.61 (95% confidence interval 0.38 to
0.98) at index hospitalization. Hence, there does not appear to be
an early hazard to an invasive strategy when glycoprotein IIb/IIIa
receptor antagonists are used upstream of PCI. Early myocardial
infarctionwas reduced by an invasive strategy based onTACTICS-
TIMI 18 data at 30 days; relative risk 0.53 (95% confidence inter-
val 0.35 to 0.79). Intermediate myocardial infarction was not de-
creased by an invasive strategy although significant heterogeneity
p<0.01 was detected when 6 month data from TACTICS-TIMI
18 were combined with 1 year data from ICTUS. The cause for
this heterogeneity may be that, in contrast to ICTUS, the TAC-
TICS-TIMI 18 investigators did not routinely measure CK-MB
post-PCI (Table 2).
Death or Myocardial Infarction (Index, Early, Intermediate):
Data for this end point were only available from TACTICS-TIMI
18. At index there was no difference between the treatment strate-
gies. The invasive strategy was associated with an early (30 day)
relative risk of 0.67 (95% confidence interval 0.48 to 0.94). Base-
line troponin levels were available from 1826 of 2220 trial par-
ticipants and this data formed the basis for the pre-specified sub-
group analysis based on TnT levels being greater than (troponin
positive) or less than (troponin negative) 0.01 ng/ml. Subgroup
analysis showed that the early (30 day) benefit of the invasive strat-
egy only reached statistical significance in troponin positive pa-
tients; relative risk 0.50 (95% confidence interval 0.32 to 0.79).
Troponin negative patients did not show significant benefit at 30
days follow up; relative risk 1.13 (95% confidence interval 0.49
to 2.63) although this confidence interval overlaps with those of
troponin positive patients. In contrast, at intermediate (6 month)
follow up, the invasive strategy did not show any benefit, regard-
less of baseline TnT status or gender. The results of this subgroup
analysis changed when the TACTICS-TIMI 18 investigators used
a different cardiac biomarker. With subgroup analysis based on a
TnI cut-off of 0.1 ng/ml, troponin positive patients showed early
(30 day) and intermediate (6 months) benefits of an invasive strat-
egy with relative risks of 0.47 (95% confidence interval 0.30 to
0.73) and 0.67 (95% confidence interval 0.47 to 0.96) respec-
tively. Such subgroup analysis based on troponin was pre-specified
by the TACTICS-TIMI 18 investigators but should nevertheless
be interpreted with caution.
Analysis 3: Routine stent use but no routine glycoprotein IIb/
IIIa receptor antagonist use. RITA-3, FRISC-II&VINO 2002
Death (Index, Early, Intermediate, Late):
There was a non-significant trend to increased death at index hos-
pitalization and no effect on early death in the invasive strategy
group. Intermediate death at 6-12 months was not significantly
improved by an invasive strategy and significant heterogeneity was
noted (p=0.02). This may have been driven by the stringent cri-
teria set by the FRISC-II group to define failure of conservative
therapy and by the large benefit of an invasive strategy observed in
the small VINO study which randomized patients with the high-
est death rates of all the included studies (Table 1). The FRISC-II
investigators undertook subgroup analysis based on the presence
of TnT greater than or less than 0.03 ng/ml and the presence of ST
depression on admission ECG. Mortality, assessed at 1 year was
not affected by an invasive strategy in this retrospective analysis,
even in the group of patients with both TnT>0.03 ng/ml and ST
depression, although the numbers of patients may be too small
to detect a difference. Follow up for late death was only provided
by FRISC-II at 2 years and RITA-3 at 5 years and was significant
improved by an invasive strategy (see analysis 1).
Myocardial Infarction (Index, Early, Intermediate, Late):
There were no differences in index myocardial infarction rates be-
tween the two strategies although significant heterogeneity was
found (p=0.07). The FRISC-II data show a significant hazard for
this end point in the early invasive group; relative risk 2.22 (95%
confidence interval 1.46 to 3.36). Importantly, the three studies
in this analysis did not undertake routine enzyme measurements
post-PCI as the ICTUS trial did and used clinical symptoms as
a diagnostic criterion (Table 2). Significant heterogeneity may be
due to the VINO definition of myocardial infarction which ex-
cluded events within 72 hours of randomization in calculating this
end point. A hazard of the invasive strategy at index hospitalization
would be expected; especially as these trials did not employ rou-
tine glycoprotein IIb/IIIa receptor antagonist use with PCI. Early
9Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
myocardial infarction, based on 30 day VINO data and 4 month
RITA-3 data, was not significantly altered by an early invasive
strategy. Intermediate (6 month data from VINO and 12 month
data from FRISC-II and RITA-3) and late myocardial infarction
(2 year FRISC-II data and 5 year RITA-3) data were significantly
decreased by the invasive strategy; relative risk 0.72 (95% confi-
dence interval 0.52 to 0.98) and relative risk 0.75 (95% confi-
dence interval 0.61 to 0.91) respectively.
Death or Myocardial Infarction (Index, Early, Intermediate,
Late):
The invasive strategywas associatedwith a trend to increased death
or non-fatal myocardial infarction at index hospitalization. Sig-
nificant heterogeneity (p=0.06) was found, with FRISC-II data
showing a significant hazard of the invasive strategy; relative risk
2.07 (95% confidence interval 1.42 to 3.03). Possible reasons for
the trend to hazard are similar to those discussed above for in-
dex myocardial infarction. Early death or non-fatal myocardial in-
farction based on VINO 30 day data did not show a significant
benefit with the invasive strategy. Intermediate death or non-fatal
myocardial infarction also did not show a significant benefit of an
invasive strategy although significant heterogeneity was found (p=
0.09) driven by results of the small VINO trial favoring the inva-
sive strategy. Although the VINO trial was small, the participants
of this trial had the highest mortality rates (Table 1) and hence it is
possible that these patients have the most to gain from an invasive
strategy. Late death or non-fatal myocardial infarction, based on
the 2 year results from FRISC-II and 5 year results of RITA-3 is
described in analysis 1.
The FRISC-II data showed that the benefit of the invasive strategy
in the end-point of intermediate (6-12 month) death or non-fa-
tal myocardial infarction was only significant in patients with ST
depression at entry. The relative risk for this end point was 0.66
(95% confidence interval 0.50 to 0.88) at 6 and 12 months for
patients who had ST depression. There was no benefit from a rou-
tine invasive strategy in patients without ST depression although
such retrospective subgroup analysis needs to be interpreted with
caution. Further, the FRISC-II troponin subgroup analysis found
that troponin positive participants (TnT>0.1 ng/ml) had a relative
risk of 0.71 (95% confidence interval 0.53 to 0.93) at 12 months
whereas participants with TnT <0.1 ng/ml had only a trend for
benefit with a relative risk of 0.77 (95% confidence interval 0.53
to 1.11). Again, the confidence intervals of these subgroup anal-
yses overlap and the results should be regarded with caution. In
a separate report, the FRISC-II investigators undertook subgroup
analysis based on the presence of TnT greater than or less than
0.03 ng/ml and the presence of ST depression on admission ECG.
The intermediate (1 year) death or non-fatal myocardial infarction
endpoint was only decreased significantly in the group of patients
with both TnT >0.03 ng/ml and ST depression >0.1 mV; relative
risk 0.60 (95% confidence interval 0.43 to 0.82).
Safety End Points:
Procedure-Related myocardial infarction:
Data from FRISC-II, RITA-3 and ICTUS showed that the inva-
sive strategy was associated with an increased risk of procedure-
related myocardial infarction; relative risk 2.05 (95% confidence
interval 1.56 to 2.70). No heterogeneity was found despite the dif-
ferent diagnostic criteria: routine measurement of CK-MB post-
PCI in ICTUS; FRISC-II and RITA-3 included clinical or ECG
criteria in the definition of this endpoint (Table 2). As already dis-
cussed, the significance of peri-procedural cardiac biomarker leaks
is the subject of considerable ongoing debate but can be modified
by background medications, including use of glycoprotein IIb/IIIa
receptor antagonists (Cutlip 2005).
Bleeding
The invasive strategywas associatedwith an increased risk of bleed-
ing; relative risk 1.71 (95% confidence interval 1.34 to 2.19).
Bleeding definitions varied between protocols; however, the excess
bleeding was consistently due to minor bleeding associated with
arterial access and wound site bleeding. Bleeding occurred in ~8%
of patients in the invasive arm compared to 5% of patients in the
conservative arm.
Contrast Reactions:
Allergic reactions due to contrast used in angiography were more
common in the invasive strategy than the conservative strategy.
Typically, 1%of patients assigned to an invasive strategy developed
contrast allergy. The rate in the conservative strategy depends on
the proportion that undergoes subsequent angiography and this
will depend on the population risk level. Contrast-induced renal
failure was not reported; however this outcome can be modified by
the patient’s baseline renal function, hydration status and sodium
bicarbonate.
Sensitivity Analysis
Changing the methods for analysis from random effects model-
ing to a fixed effects model altered the interpretation of the data.
Most notably the early and intermediatemyocardial infarction end
point in analysis 1 showed a significant benefit as a result of the
invasive strategy. However, random effects modeling was chosen
for the final presentation of the results as it provides a more con-
servative estimate of effect size in the presence of a small number
of included studies and variable risk levels of randomized partic-
ipants. Table 1 highlights important differences between the in-
cluded studies which guided the choice of sensitivity analysis based
on exclusion of certain studies. Recurrent angina and rehospital-
ization are end points that were not subjected to sensitivity analysis
because relative risk estimates were the most consistent and robust
findings of this meta-analysis and, in general, were not associated
with significant heterogeneity. Further, the composite end point of
death or non-fatal myocardial infarction was not reported by the
ICTUS investigators and hence this end point was not subjected
to sensitivity analysis. The myocardial infarction end point was
not subjected to sensitivity analysis because of the variable defini-
tions used in the included studies and the small numbers of trials.
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Consequently the analyses below relate to the mortality end-point
only.
Time to Angiography:
As previously discussed, time to angiography in the invasive arm
may influence outcomes. Indeed, Neumann et al showed that in
patients with UANSTEMI, a “delayed invasive” strategy with an-
giography 3-5 days post-randomization had a relative risk of death
or non-fatal myocardial infarction which was roughly two fold
that observed in patients with an “early invasive” strategy where
angiography was performedwithin 6 hours of randomization. The
excess events in the late invasive arm occurred prior to angiogra-
phy; thiswas observed despite background antithrombotic therapy
which included aspirin, clopidogrel, tirofiban and heparin. No-
tably, this study randomized a high risk population with roughly
two thirds of the participants having a positive troponin and ST
depression on ECG (Neumann 2003). Times to angiography in
the included trials are shown in the table of included studies and
can be grouped as “early invasive” strategy versus “delayed inva-
sive” strategy. ICTUS, TACTICS-TIMI 18 and VINO generally
employed angiography within 24 hours of randomization whereas
the delay in FRISC-II and RITA-3 was typically greater than 2
days. Sensitivity analysis based on this study categorization did
not yield results different from the previously reported findings of
this review.
Mortality Rates In the Conservative Arm:
The mortality rates of the included studies are described in Table
1 as the mortality rate in the conservative arm divided by the
number of years of follow up. ICTUS, FRISC-II and RITA-3 had
mortality rates 2.5-2.8% per year of follow up while TACTICS-
TIMI 18 had a rate of 7% and VINO a rate of 27%. Hence, the
data for ICTUS, FRISC-II and RITA-3 were analyzed separately
as were data for TACTICS-TIMI 18 and VINO.When the high-
mortality rate studies and low-mortality rate studies were analyzed
separately, the previously reported findings of the review were not
altered.
Percentage Of Trial Participants With a Positive Troponin:
Findings on subgroup analysis have suggested that a positive tro-
ponin may identify high risk patients who may show particular
benefit with an early invasive strategy. While VINO and ICTUS
only recruited participants with positive cardiac biomarkers, the
percentage of biomarker-positive patients in FRISC-II, RITA-3
and TACTICS-TIMI 18 range between 50% and 75% (Table
1). The studies that only randomized biomarker-positive patients
(VINO and ICTUS) were analyzed separately and showed a null
effect on intermediate mortality. When the studies that did not
specify cardiac biomarker status as an inclusion criterion were an-
alyzed separately, there was a significant increase in index death in
the invasive arm; relative risk 1.72 (95% confidence interval 1.05
to 2.82). This finding highlights potential hazards of an early inva-
sive strategy and the importance of risk stratification to select high
risk patients who may have meaningful benefits that outweigh the
harms.
CABG as a Mode of Revascularization in the Invasive Arm:
Data from trials of coronary revascularization in patients with
stable CAD suggest that CABG may be the preferred mode of
revascularization in higher risk patients with multivessel disease
(Rihal 2003) and reduce death over long term follow up (Yusuf
1994). Rates of CABG as mode of revascularization in the invasive
arms of the included studies are described in Table 1. ICTUS and
TACTICS-TIMI 18 had rates of ~20% while RITA-3, FRISC-II
and VINO had rates of ~40%. Performing a sensitivity analysis
on the basis of high or low rates of CABG in the invasive arm used
the same data as already used in analysis 2 & analysis 3 and hence
the findings were identical to those already described.
Difference in Revascularization Rates Between the Treatment
Arms:
The absolute percentage difference in revascularization rates be-
tween the invasive and conservative arms of each trial is described
in Table 1. FRISC-II and VINO had higher absolute differences
in revascularization rates (35 to 39%) compared to the other in-
cluded trials (17 to 25%). When the former trials were pooled,
a significant reduction in intermediate death was noted; relative
risk 0.49 (95% confidence interval 0.25 to 0.95). This suggests
as the difference in rates of revascularization between invasive and
conservative arms narrows, the beneficial effect on mortality of a
routine invasive strategy may diminish.
D I S C U S S I O N
Summary of findings:
In the all-study combined analysis, index death (during initial hos-
pitalization) showed a trend to hazard with an invasive strategy
with a relative risk of 1.59 (95% confidence interval 0.96 to 2.64).
Early death (<4 months) and intermediate death (6-12 months)
were not significantly improved with an invasive strategy and sig-
nificant heterogeneity was found in this analysis possibly driven by
the different levels of risk, different rates of background medical
therapies and different criteria for ischemia in the included stud-
ies. Late death (2-5 years) was significantly decreased by an inva-
sive strategy with a relative risk of 0.75 (95% confidence interval
0.62 to 0.92) based on data from two trials that provided long
term follow up. Index myocardial infarction was not significantly
improved with an early invasive strategy; significant heterogeneity
was found on combining data. Myocardial infarction data at index
hospitalization from trials that routinely used glycoprotein IIb/IIIa
receptor antagonists were only available fromTACTICS-TIMI 18
which showed a significant benefit of the early invasive strategy
with a relative risk ratio of 0.61 (95% confidence interval 0.38 to
0.98). Early and intermediate myocardial infarction was not im-
proved with an invasive strategy and significant heterogeneity was
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found at these time points. Late myocardial infarction (2-5 years)
was significantly improved by an invasive strategy with a relative
risk of 0.75 (95% confidence interval 0.61 to 0.91) based on data
from two trials that provided long term follow up. The ICTUS
trial did not provide data for the composite end point of death or
non-fatal myocardial infarction. Analysis of available data for this
end point suggest that benefits of an early invasive strategy were
significant only in trial participants with high risk characteristics
i.e. positive troponin or ST depression on admission ECG. These
markers of risk may have identified populations with higher event
rates and hence enhanced power to detect a difference between the
two strategies; the confidence intervals between subgroups over-
lapped and these findings from post-hoc analyses should be inter-
preted with appropriate caution. Early and intermediate refractory
angina were both significantly decreased with an early invasive
strategy; early relative risk 0.47 (95% confidence interval 0.32 to
0.68) and intermediate relative risk 0.67 (95% confidence interval
0.55 to 0.83). Early and intermediate rehospitalization were both
significantly decreased with an early invasive strategy; early relative
risk 0.60 (95% confidence interval 0.41 to 0.88) and intermediate
relative risk 0.67 (95% confidence interval 0.61 to 0.74). With
regards to safety end points, the invasive strategy was associated
with a two fold increase in the relative risk of the variably defined
procedural myocardial infarction end point and a 1.7 fold increase
in the relative risk of bleeding, but no increase in relative risk of
stroke. The excess in bleeding is mainly due to wound site bleeding
but is difficult to grade due to inter-trial differences in definition
and reporting of data.
Discussion of findings on subgroup analysis:
Troponin Status of Patients:
Troponin status of the patients serves as an important tool for
risk stratification. Of the included studies, only TACTICS-TIMI
18 had the pre-specified intention of testing the “troponin hy-
pothesis” i.e. to test whether benefit from an invasive strategy was
limited to troponin positive patients. Data for the death or non-
fatal myocardial infarction end point from TACTICS-TIMI 18
and FRISC-II suggest that only high risk patients with a posi-
tive troponin benefited from an early invasive strategy with re-
spect to this end point. However, the confidence interval for this
subgroup analysis showed overlap with that of troponin negative
patients. Data from VINO, which only enrolled patients with
clinical symptoms, ECG changes and positive cardiac biomarkers
showed a significant 72% relative risk reduction in this end point
at 6 months. However, the ICTUS trial which also exclusively en-
rolled troponin positive patients had an unexpectedly low baseline
mortality rate when compared to other included studies (Table 1).
This may be partly due to optimal medical therapy being seen in
the ICTUS trial compared to other trials wherein, in both arms,
early use of clopidogrel and intensive lipid-lowering therapy were
recommended to treating clinicians. Disparate event rates in pa-
tients with positive troponin highlights the importance of global
risk stratification as opposed to using cardiac bio-markers as a sin-
gle risk index . Indeed, in retrospective analysis of the FRISC-II
data (Diderholm 2002), death or non-fatal myocardial infarction
showed a significant 40% relative risk reduction only in patients
with both TnT > 0.03 ng/ml and ST depression on admission
ECG. Hence, although ICTUS participants all had a TnT >0.03
ng/ml, this sole criterion did not necessarily identify a risk level
that may be benefited by an invasive strategy.
A retrospective analysis by the TACTICS-TIMI 18 investigators
highlights the limitations of purely using a positive troponin to
predict event rates. An analysis of the invasive arm showed that
6% of the patients who had a positive troponin test did not have
significant angiographic CAD as defined by a >50% stenosis of
any coronary artery (Dokainish 2005). At six months, these pa-
tients had a 3.1% rate of death or re-infarction compared to 0%
for those with a negative troponin and no angiographic CAD. As
would be expected, troponin positive patients with angiographic
CAD had a high 8.6 % rate of death or re-infarction at 6 months.
Surprisingly, patients with angiographic CAD who had a negative
troponin had a 5.8% rate of death or re-infarction at 6 months
which is clearly higher than that for troponin positive patients
without CAD.Hence, troponin alone cannot be used to risk strat-
ify patients and this analysis highlights the limitations of angiog-
raphy in the assessment of plaque burden. In general, in unstable
angina studies, a positive troponin status has been shown to cor-
relate with complex coronary lesions on angiography and reduced
coronary flow (Benamer 1999; Heeschen 1999a; Hochman 1999)
but should not be used alone to identify a high risk population.
However, absolute values of troponin show a linear relation with
subsequent risk of coronary events and troponin positivity has also
been shown to predict benefit from glycoprotein IIb/IIIa receptor
antagonists (Hamm 1999; Heeschen 1999b) and remain a critical
element of risk stratification.
ST Depression on Admission:
As previously mentioned, ECG changes on admission forebode
a worse prognosis in UA/NSTEMI. Indeed, data from the TIMI
III registry show that patients with ST depression on the admis-
sion ECG have a 2.5 fold increase in risk of death or myocardial
infarction at 1 year (Cannon 1997). As discussed above, post-hoc
analysis of FRISC-II data showed that the benefit of an early in-
vasive strategy on the end point of death or non-fatal myocardial
infarction only reached statistical significance in patients with ST
depression on the admission ECG. In FRISC-II and the TIMI
III registry, the prevalence of triple vessel or left main disease was
approximately 50% and 66% respectively in patients who had ST
depression on admission ECG. Hence, the ECG can be used as a
tool to identify patients that are likely to benefit from revascular-
ization. An analysis of the FRISC-II data showed that ST depres-
sion was still a predictor of benefit from an invasive strategy even
after baseline differences were accounted for (Holmvang 2003).
Further, this analysis also suggested that the benefits of the invasive
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strategy were further amplified with increasing amplitude of ST
depression in an increasing number of ECG leads.
Data from TACTICS-TIMI 18 confirms the utility of ST seg-
ment changes in identifying a higher risk population that may
benefit from an invasive strategy. Unfortunately, data could not
be obtained for the end point of death or non-fatal myocardial
infarction but the study includes data for the end point of death/
non-fatal myocardial infarction/rehospitalization for ACS. Using
this end point, the relative risk was 0.62 (95% confidence interval
0.53 to 0.74) in participants with baseline ST changes while a null
effect was observed in those without such changes. The percentage
of trial participants with ST depression on index ECG is described
in Table 1; however data for subgroup analysis were not provided
in all the included studies. While subgroup analyses of ST depres-
sion and troponin status may identify populations with increased
risk and hence an increased power to detect statistical significance
such post hoc analyses should be interpreted with caution.
Gender:
There were disparate findings between analysis 2 and analysis 3
on the impact of gender on outcomes. TACTICS-TIMI 18 found
no significant interaction between gender and outcomes based on
treatment strategy. This was contrary to the findings of analysis 3
which showed that benefit from the invasive strategy only reached
statistical significance in males. In the combined analysis (analysis
1), gender sub-analysis for intermediate death or non-fatal my-
ocardial infarction showed that the benefit of the invasive strategy
was confined to males who showed a significant 32% relative risk
reduction. However, the number of women in the included stud-
ies was small and this decreased power to detect benefit from an
invasive strategy as is highlighted by the wide confidence intervals.
Women with UA/NSTEMI differ from men with the condition
and this warrants further discussion.
The included studies have shown that women exhibit less severe
coronary artery disease and are less likely to have elevated troponin
when compared to men (Clayton 2004; Glaser 2002; Lagerqvist
2001). Further, in FRISC-II and RITA-3, women in the conser-
vative arm had a better prognosis than men in the conservative
arm. There is no a priori reason why the finding of a significant
2.1 fold relative risk of peri-procedural myocardial infarction in
the invasive arm would not also apply to women despite their
less extensive CAD on angiography. However, no such hazard was
observed in TACTICS-TIMI 18; possibly because tirofiban was
used upstream of invasive procedures. A retrospective analysis of
TACTICS-TIMI 18 data suggests that, after adjusting for differ-
ences in baseline characteristics, the benefits of an early invasive
strategy in women were the same as those seen in men (Glaser
2002). In contrast, similar analyses undertaken by FRISC-II and
RITA-3 investigators did not show a benefit for the invasive strat-
egy in women even after adjustment for baseline characteristics.
The RITA-3 analysis suggested that women had better outcomes
than men when managed conservatively and did not benefit from
an invasive strategy even when women with high risk features were
analyzed separately (Clayton 2004). Women in TACTICS-TIMI
18 and RITA-3 were less likely than men to undergo CABG, even
when adjusted for the presence of three vessel disease or left anterior
descending artery disease (Clayton 2004; Glaser 2002). Notably,
inFRISC-IIwhere the rates ofCABGwere similar in bothmen and
women, the one year mortality rate in patients undergoing CABG
was 9.9% in women compared to 1.2% in men (Lagerqvist 2001).
Higher operative CABG mortality has been observed in women
enrolled in observational studies and this discrepancy could not be
accounted for by age, co-morbidities or smaller body surface area
(Blankstein 2005). The retrospective analyses from the included
studies should be interpreted with appropriate caution but high-
light the importance of further research into this topic and the
importance of risk stratification; especially in women who are less
likely to have angiographic CAD when compared to their male
counterparts.
The importance of global risk stratification:
As the above discussion highlights and as sub-group analyses have
illustrated, risk stratification is an integral component of manag-
ing patients with UA/NSTEMI. The goal of risk stratification is to
identify patients with a high likelihood of complicated coronary
artery disease who are at increased risk of recurrent coronary events
or premature death and offer such patients the benefits of revas-
cularization. However, the clinical distinction between UA and
NSTEMI does not adequately stratify high risk patients (Zaacks
1999). Consequently, the current AHA guidelines recommend the
use of several parameters for risk stratification (Braunwald 2002)
e.g. the TIMI risk score (Antman 2000). To underscore this point,
in a post-hoc analysis of the FRISC-II data, participants with tro-
ponin T >0.03 ng/ml as well as ST depression showed statistically
significant benefit with an early invasive strategy whereas partici-
pants with only one of these variables did not (Diderholm 2002).
Only TACTICS-TIMI 18 undertook sub-analyses based onTIMI
risk scores. The participants were stratified into 3 categories based
on their TIMI risk score; low, intermediate or high risk. The study
showed that only intermediate and high risk patients benefited
from the invasive strategy with regards to the primary end point of
death or non-fatal myocardial infarction or rehospitalization for
ACS. Unfortunately, data for the end point of death or non-fatal
myocardial infarction were unavailable and could therefore not be
incorporated into this review.
The TIMI score was extracted from the unfractionated heparin
arm of the TIMI 11B trial (TIMI 11B 1999) and was validated
in the enoxaparin arm of TIMI 11B and in both arms of the
ESSENCE (ESSENCE 1997) trial. The risk score was shown to
be a valid predictor of all cause mortality, myocardial infarction or
urgent revascularization within 14 days of randomization. Impor-
tantly, the TIMI score was also a predictor for each of the compo-
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nents of this composite end point (Antman 2000). The TIMI risk
score has been subsequently validated in the TIMI III registry of
unselected UA/NSTEMI patients and was shown to predict the
end point of death, myocardial infarction or recurrent ischemia
and the components of the composite at six weeks and one year
(Scirica 2002). Further, the TIMI risk score was also validated for
the death, myocardial infarction or recurrent ischemia end point
at up to 6 months in the PRISM-PLUS trial and was also shown
to predict benefit from tirofiban, even in patients with negative
CK-MB (Morrow 2002). Hence, this versatile risk score is able to
identify patients with high event rates who may also benefit from
an invasive strategy. Intuitively, one would expect that patients
with higher TIMI scores and therefore a higher risk for mortality
and recurrent events have more extensive CAD on angiography.
This has been confirmed in a retrospective analysis of patients with
UA/NSTEMI (Garcia 2004). These findings were also confirmed
by a retrospective analysis by the PRISM-PLUS investigators who
also showed the TIMI score to correlate with impaired epicardial
artery blood flow and the presence of visible thrombus on angiog-
raphy (Mega 2005). Although there are other published risk scores
for UA/NSTEMI (Goncalves 2005), the TIMI risk score is per-
haps the most widely used. Further, the low event rates in ICTUS
which exclusively enrolled troponin positive patients highlight the
importance of considering multiple variables in risk stratification.
Indeed, on 5 year follow up by the RITA-3 investigators, 9 factors
other than treatment group emerged as multivariate predictors of
death or non-fatal myocardial infarction (Fox 2005). When the
logistic coefficients for the risk factors were added and the study
population divided into quartile based on risk score, patients in
the highest quartile of risk score showed substantially more benefit
from an invasive strategy.
Current “real world” event rates in patients with UA/NSTEMI
compared to rates observed in the included trials:
The GRACE registry, which collects data from 14 countries, has
reported mortality rates at 6 months post-discharge in patients
hospitalizedwith various forms of acute coronary syndrome. Entry
criteria for this registry include a history of chest pain and one of
the following: ischemic ECG changes, increased cardiac biomark-
ers or a documented history of CAD. The in-hospital mortality
rates for patients recruited between 1999-2002 were 5.9% for pa-
tients with NSTEMI and 2.7% for patients with unstable angina.
Also, the 6 month post-discharge mortality rates were 6.2% and
3.6% for NSTEMI and unstable angina respectively (Goldberg
2005). Further, re-hospitalization rates at 6months post-discharge
were about 20%. In another report from the GRACE registry
that included patients recruited between 1999 and 2003, the 6
month post-dischargemortality rates were reported as 11.6% from
NSTEMI and 6.8% for unstable angina (Van de Werf 2005).
Clearly, the mortality rates from this real-world registry are higher
than those observed in the included studies as shown in Table 1.
However, these patients did not receive optimal medical manage-
ment in that only ~50% of NSTEMI patients received ACE in-
hibitors, heparin or statins (Goldberg 2005). While >90% of pa-
tients received aspirin and >80% received beta blockers, only 25%
received glycoprotein IIb/IIIa receptor antagonists and it is likely
few would have received clopidogrel as the patients studied were
entered into the registry prior to the publication of the CURE trial
(CURE 2001) and before use of clopidogrel for UA/NSTEMI
became accepted as standard therapy. Similarly, patients enrolled
in UA/NSTEMI trials received higher rates of medical therapy
than patients enrolled in theCRUSADE registry (Kandzari 2005).
However, the discrepancy in mortality rates between the partici-
pants in the included studies of this review and registry reported
mortality rates is arguably too high to be explained by advances
in medical management of UA/NSTEMI alone. Another expla-
nation may be that selection and recruitment protocols may bias
trials to enrolling patients with a risk lower than that seen in uns-
elected patients entered into registries. While analysis of available
data suggests that high risk patients may benefit from an invasive
strategy, this absolute benefit is likely to narrow as early medical
therapies and risk stratification procedures for UA/NSTEMI im-
prove, combined with appropriate use of deferred coronary an-
giography and revascularization. This is the message arising from
ICTUS which constitutes themost contemporary trial which pro-
moted optimal medical management and risk stratification. This
implies that only progressively higher risk patients will continue
to benefit from early invasive intervention in the future. Alterna-
tively, lack of benefit in regards to several end points in this review
may be due to lower-risk patients being selected for trial enrol-
ment.
Findings from studies in the pre-stent era and other reviews
on this topic :
Two trials that were undertaken in the pre-stent era: TIMI-3b and
VANQWISH 1998. The early invasive arm of TIMI-3b involved
cardiac catheterization at an average 36 hours of randomization
and coronary revascularization by coronary angioplasty or CABG.
The early invasive strategy had no effect on hard clinical endpoints
of death,myocardial infarction, stroke or the composite of death or
myocardial infarction. As is consistentwithmore recent clinical tri-
als, the early invasive strategy reduced recurrent hospitalization at
both 6weeks and 1 year with relative risks of 0.54 (95%confidence
interval 0.40 to 0.74) and 0.79 (95% confidence interval 0.68 to
0.93) respectively (TIMI-3b). In TIMI-3b, an early invasive strat-
egy did not reduce the need for angina medications at one year. In
contrast, the VANQWISH study showed a hazard associated with
the early invasive strategy which involved cardiac catheterization
at an average 48 hours after randomization. Indeed, the early inva-
sive strategy was associated with an increased relative risk of mor-
tality at hospital discharge, one month and one year with relative
risks of 3.47 (95% confidence interval 1.41 to 8.52), 2.53 (95%
confidence interval 1.19 to 5.42) and 1.60 (95% confidence in-
terval 1.08 to 2.37) respectively (VANQWISH 1998). Similarly, a
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hazard was associated with the early invasive strategy for the com-
posite end point of death or non-fatal myocardial infarction. The
hazard of an early invasive strategy on these end points ceased to
be significant by the end of the study (average 23 months). Forty
four percent of patients in the invasive arm of this trial underwent
a revascularization procedure; 47% of which involvedCABG. The
mortality associated with CABG in the invasive arm was 11.6%
compared to 3.4% in the conservative arm and this discrepancy
has been cited as an explanation for the increased mortality in the
early invasive arm of the VANQWISH trial (Braunwald 2003).
Not surprisingly, rates of background medical therapy were low
by contemporary standards; glycoprotein IIb/IIIa receptor antag-
onists, ticlopidine or statins were not routinely used. Further, the
VANQWISH protocol stipulated that beta-blocker and heparin
use be physician initiated.
Not surprisingly, two recent meta-analyses on this topic that in-
cluded the aforementioned old trials and the MATE 1998 trial
reached different conclusions to the ones presented here (please
see table of excluded studies for exclusion reasons). These reviews
did not include the most recent trial, the ICTUS study. The re-
view byMehta et al showed that an invasive strategy was associated
with mortality hazard from randomization to hospital discharge;
relative risk 1.61 (95% confidence interval 1.14 to 2.27) (Mehta
2005). An early hazard with an invasive strategy was not found
in this review, possibly because outdated studies were excluded.
When Mehta et al analyzed outcomes from hospital discharge to
end of follow up, the early invasive strategy was associated with
reductions in death and reductions in non-fatal myocardial infarc-
tion with relative risks of 0.78 (95% confidence interval 0.64 to
0.94) and 0.56 (95% confidence interval 0.47 to 0.68) respec-
tively. This is consistent with the finding of late benefit in this
review. When Mehta et al analyzed trial data from randomization
to end of follow up, the invasive strategy had a null effect on mor-
tality but a reduction in non-fatal myocardial infarction; relative
risk 0.77 (95% confidence interval 0.67 to 0.89). The null effect
on mortality observed may be driven by early hazard of an inva-
sive strategy seen in older trials e.g. VANQWISH. This review
analyzed the endpoints at certain time points since it was felt that
combining outcomes collected from studies with short duration (6
months) with those of long duration (5 years) would not provide a
meaningful point estimate (see table of included studies). Indeed,
a significant risk reduction in mortality with an invasive strategy
was only evident in trials with long term follow up. A significant
reduction in recurrent angina and rehospitalization with an inva-
sive strategy was a consistent finding across all reviews (Choudhry
2005; Mehta 2005).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The most consistent and robust findings of this review are that
an invasive strategy in UA/NSTEMI results in a significant 33%
relative risk reduction for both the end points of refractory angina
and rehospitalization at 6-12 months. While the invasive strategy
is associated with a two fold increase in the risk of peri-procedu-
ral myocardial infarction, the available data suggest a significant
25% relative risk reduction for both the end points of death and
myocardial infarction assessed at 2-5 years, Hence the early hazard
associated with a routine invasive strategy must be weighed against
potential long term benefit in clinical end points. However, longer
term follow-up of more contemporary trials may show this benefit
to be attenuated by more optimal use of medical therapies and
deployment of more rigorous risk stratification protocols in the
days immediately following onset of the acute event. The benefits
of an early invasive strategy may be moremeaningful in higher risk
patients who would be expected to have a lower number needed
to treat. The data presented in this review suggest that an early
invasive strategy is superior to a conservative strategy.
Implications for research
This review has highlighted the deficit in the data that exist to
answer the important question of whether a routine early invasive
strategy is superior to a conservative, ischemia-guided strategy in
the optimalmanagement ofUA/NSTEMI in current practice. The
trials have enrolled heterogeneous populations of patients with
variable levels of risks and event rates, and subject to varying co-
interventions, and have used outcome measures subject to vari-
able definition and timing. Risk stratification of the participants
in each trial based on a validated risk system (e.g. the TIMI risk
score) would allow for more meaningful meta-analyses of avail-
able data and provide a risk score or an absolute event rate above
which an invasive strategy is expected to significantly improve out-
comes. Clearly, as medical therapies for UA/NSTEMI improve,
progressively less absolute benefit is to be gained by intervention
and hence the risk at which invasive intervention is warranted is
likely to represent a moving target. Another major limitation to
the analyses undertaken in this review is the underpowering of
trials regarding the effects of an invasive strategy on all-cause mor-
tality due to the short length of follow up, and in interpretation
of sub-group analyses. This could be addressed in future clinical
trials by ensuring sufficient events to accrue by way of either larger
sample sizes, enrolment of higher risk patients or longer follow-
up. Finally, further research is required to better define the benefits
and hazards of an invasive strategy in females.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
FRISC-II
Methods randomization: an independent organization randomized patients using telefax
blinding: non-blinded
selection bias & intention-to-treat analysis: all patients accounted for by end of trial; intention-to-treat analysis used
Participants 2457 patients with anginal pain within the last 48 hours and ST depression or elevated cardiac markers
overall impression of patient risk level: intermediate-high
Interventions conservative arm: aspirin, beta blocker, statin, ACEI, dalteparin or UFH
invasive arm: as above & routine angiography (average 4d). 10% glycoprotein 2b/3a receptor antagonist use
Outcomes death all causes (6, 12, 24 months), non-fatal MI (6, 12, 24 months), refractory angina (6 months), death or non-
fatal MI (6, 12, 24 months), rehospitalization (6 weeks, 6 , 12 months), procedural MI, bleeding, contrast allergy
Notes
ICTUS
Methods randomization: centralized system; randomized by telephone
blinding: end points were adjudicated by a blinded committee
selection bias & intention-to-treat analysis: six patients lost to follow up; intention-to-treat analysis used
Participants 1200 patients with accelerating angina or angina at rest in the preceding 24 hours & an elevated cardiac troponin
T >0.3 microg/litre AND either ischemic ECG changes OR documented history of CAD (previous catheterization,
history of myocardial infarction or positive exercise test)
Overall impression on level of risk in patients: high risk; all patients had a positive troponin test on randomization
Interventions conservative arm: aspirin, enoxaparin, statin, clopidogrel
invasive arm: as above, abciximab & routine angiography median time 23 hours post-randomization. 94% glyco-
protein 2b/3a receptor antagonist use
Outcomes death all causes (1 year), non-fatal MI (1 year), rehospitalization (1 year)
Notes
RITA-3
Methods randomization: central telephone service
blinding: open
selection bias & intention-to-treat analysis: all patients accounted for at 2 years; intention-to-treat analysis used.
While 99.8% of patients were followed up for at least 3 years, this figure was 59% at 5 years
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RITA-3 (Continued)
Participants 1810 patients with chest pain within the last 72 hours, a documented history of coronary artery disease (CAD) &
one of the following: ischemic ECG changes or Q waves suggesting previous MI or proven CAD on angiogram.
Excluded those with probable evolving MI or those with elevated enzymes (2x) before randomization.
Overall impression on level of risk in patients: Intermediate
Interventions conservative arm: aspirin, beta blocker, enoaxaparin
invasive arm: as above&routine angiography (median 2d for angiogram). 25%glycoprotein 2b/3a receptor antagonist
use
Outcomes death all causes (4, 12, 24 months, 5 years), non-fatal MI (4, 12, 24 months, 5 years), refractory angina (4,12 mo),
death or non-fatal MI (4, 12, 24 months, 5 years), procedural bleeding & MI
Notes
TACTICS-TIMI 18
Methods randomization: centralized system
blinding: end points were adjudicated by a blinded committee
selection bias & intention-to-treat analysis: all patients accounted for by end of trial; intention-to-treat analysis used
Participants 2220 patients with angina (accelerating or prolonged) at rest in preceding 24 hours & at least one of the following:
ischemic ECG changes, elevated cardiac markers or documented CAD (previous catheterization, revasc or MI)
Overall impression on level of risk in patients:variable; subanalyses reported on TIMI risk score & troponin status
Interventions conservative arm: aspirin, beta blocker, UFH, tirofiban, statin
invasive arm: as above & routine angiography (median 22h for angiogram). 94% glycoprotein 2b/3a receptor antag-
onist use
Outcomes death all causes (30 days, 6 months), refractory angina (6 months), death or non-fatal MI (30 days, 6 months),
rehospitalization (30 days, 6 months)
Notes
VINO 2002
Methods randomization: sealed envelopes
blinding: open
selection bias & intention-to-treat analysis: all patients accounted for by end of trial; intention-to-treat analysis used
Participants 131 patients with ischemic chest pain lasting more than 20 minutes (within the preceding 24 hours) + ECG changes
+ elevated cardiac markers
Overall impression on level of risk in patients: high; all patients were cardiac biomarker positive
Interventions conservative arm: aspirin, beta blocker, UFH,
invasive arm: as above & routine angiography (average 6.2h for angiogram post-randomization). 0% glycoprotein
2b/3a receptor antagonist use
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VINO 2002 (Continued)
Outcomes death all causes (30 days, 6 months), non-fatal MI (30 days, 6 months), death or non-fatal MI (30 days, 6 months),
rehospitalization (30 days, 6 months)
Notes
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
GUSTO2b This is a post-hoc analysis from a trial designed to compare hirudin to heparin in UA/NSTEMI patients
MATE 1998 This trial was undertaken in the pre-stent era & included patients with STEMI
MITI 2000 This is not a randomized clinical trial. The data are extracted from a registry
Neumann 2003 This trial included UA/NSTEMI patients that were all due to have angiography. This trial compared 2 invasive
strategies depending on whether angiography was undertaken at <6hours or at 3-5 days. Hence, this trial
compared two different invasive strategies i.e. early or delayed invasive and is not appropriate for this review
TIMI-3b This trial was undertaken in the pre-stent era.
TRUCS 2000 This trial was deemed inappropriate to this review since the patients included were admitted with recurrent
angina 48 hours after the index case of unstable angina. Hence, the patients in this trial had all been managed
conservatively for at least 48 hours after their index chest pain & had to suffer another bout of angina before
randomization was considered. Studies included in this review require that patients are randomized at index
presentation. This study, by definition, only considered patients with Braunwald class IIIb or IIIc unstable
angina and is therefore dissimilar enough from the included studies to warrant exclusion
VANQWISH 1998 This trial was undertaken in the pre-stent era and included patients treated with thrombolysis
24Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. All Studies undertaken in the stent era regardless of glycoprotein glycoprotein IIb/IIIa receptor
use.
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Index Death 4 6618 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.96, 2.64]
1.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 1.99 [0.85, 4.62]
1.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 1.39 [0.65, 2.96]
2 Early Death 3 4161 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.66, 1.88]
2.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.76, 2.51]
2.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 1941 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.15, 3.02]
3 Intermediate Death 5 7818 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.57, 1.19]
3.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
2 3420 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.66, 1.39]
3.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.33, 1.37]
4 Late Death 2 4267 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.62, 0.92]
5 Index Myocardial Infarction 4 6618 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.44, 2.34]
5.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.38, 0.98]
5.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.65, 3.12]
6 Early Myocardial Infarction 3 4161 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.38, 1.06]
6.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.35, 0.79]
6.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
2 1941 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.18, 2.17]
7 Intermediate Myocardial
Infarction
5 7818 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.12]
7.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
2 3420 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.48, 2.02]
7.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.52, 0.98]
8 Late Myocardial Infarction 2 4267 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.61, 0.91]
9 Index Death or Non-Fatal MI 4 6618 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.59, 2.21]
9.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.51, 1.17]
9.2 No routine glycoprotein
IIb/IIIa receptor antagonist use
3 4398 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.75, 2.86]
10 Early Death or Non-Fatal MI 2 2351 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.45, 0.92]
10.1 Routine glycoprotein
IIb/IIIa receptor antagonist use
1 2220 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.48, 0.94]
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